Delving into the Latest Updates on Pembrolizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Lambrolizumab, Pembrolizumab (Genetical Recombination), Pembrolizumab (genetical recombination) (JAN)

+ [11]

Target

PD-1

Action

inhibitors

Mechanism

PD-1 inhibitors(Programmed cell death protein 1 inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [13]

Active Indication

Platinum-Resistant Primary Peritoneal CarcinomaPlatinum-Resistant Epithelial Ovarian CarcinomaMismatch repair-deficient Colonic Cancer+ [327]

Inactive Indication

Acral Lentiginous Malignant MelanomaAcute myeloid leukemia with mutated NPM1Adenocarcinoma, metastatic+ [111]

Originator Organization

Merck & Co., Inc.

Active Organization

Merck Sharp & Dohme Corp.

MSD R&D (China) Co. Ltd.Merck Sharp & Dohme LLC

+ [16]

Inactive Organization

Merck Sharp & Dohme (Ireland) Ltd.

Turnstone Biologics Corp.

Viralytics Pty Ltd.

License Organization

Nektar Therapeutics

NeoImmuneTech, Inc.

Canada Pension Plan Investment Board

+ [80]

Drug Highest PhaseApproved

First Approval Date

United States (04 Sep 2014),

Melanoma

RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), PRIME (European Union), Conditional marketing approval (China), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (Australia), Breakthrough Therapy (China), Priority Review (United States), Priority Review (China)

Login to view timeline

Structure/Sequence

Sequence Code 93660H

Source: *****

Sequence Code 93670L

Source: *****

This is a single center, open-label phase I clinical trial designed to determine the safety of personalized and adjusted neoantigen peptide vaccine (PANDA-VAC) administered concurrently with pembrolizumab in subjects with advanced squamous non-small cell lung cancer (NSCLC) or squamous cell carcinoma of head and neck (SCCHN).

Start Date20 May 2027

Sponsor / Collaborator

Lineberger Comprehensive Cancer Center

NCT07037004

/ RecruitingPhase 2IIT

Impact of Microbiome Modulation With CBM588 in Combination With Pembrolizumab for Adjuvant Therapy of High-Risk, Resected Renal Cell Carcinoma (RCC)

This phase II trial compares the effect of adding a Live Biotherapeutic Product called CBM588 to pembrolizumab versus pembrolizumab alone in preventing return of disease (recurrence) after surgery for patients with renal cell cancer. Pembrolizumab is an immune checkpoint inhibitor. Immunotherapy with monoclonal antibodies such as pembrolizumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Pembrolizumab is approved for the treatment of renal cell cancer after surgery. Research has shown that changes to the composition of the healthy bacteria in the body (the microbiome), may improve a patient's response to treatment with immunotherapy. CBM588, a Live Biotherapeutic Product (LBP) containing a bacteria called Clostridium butyricum, has been shown to improve outcomes in patients treated with immunotherapy for other types of cancer. Adding CBM588 to treatment with pembrolizumab after surgery may cause changes in the microbiome that improve patient response to treatment and reduce disease recurrence, compared to pembrolizumab alone.

Start Date01 Jan 2027

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT07603856

/ RecruitingPhase 2IIT

A Randomized Phase II Study of Radiotherapy Plus Immune Checkpoint Inhibitor Therapy Versus Standard of Care Chemotherapy in Patients With Metastatic or Relapsed Non-Small Cell Lung Cancer Previously Treated With Immunotherapy

Current clinical trials testing the combination of immunotherapy with radiotherapy.

Start Date12 Dec 2026

Sponsor / Collaborator

The University of Chicago

100 Clinical Results associated with Pembrolizumab

Login to view more data

100 Translational Medicine associated with Pembrolizumab

Login to view more data

100 Patents (Medical) associated with Pembrolizumab

Login to view more data

11,111

Literatures (Medical) associated with Pembrolizumab

31 Dec 2026·Human Vaccines & Immunotherapeutics

Durable response of anaplastic thyroid cancer to pembrolizumab combined with chemotherapy: A case report

Article

Author: Zhuang, Yihan ; Chen, Qiongshan ; Lin, Wen ; Chen, Zipei

Anaplastic thyroid cancer is a notoriously aggressive malignancy with a dismal prognosis, typically associated with a median overall survival of less than one year. Therapeutic alternatives are particularly limited for patients without actionable driver mutations. Here, we report a case of BRAF V600E wild-type, PD-L1-positive (tumor proportion score of 80%) anaplastic thyroid cancer with residual/relapsed disease following surgery and subsequent progression on multi-targeted tyrosine kinase inhibitor therapy. The patient was thereafter treated with a combination of pembrolizumab, nab-paclitaxel and carboplatin, resulting in a sustained near-complete response lasting over 30 months, accompanied by a manageable safety profile. The favorable response in this case suggests that further evaluation of this triplet regimen could be considered for anaplastic thyroid cancer, though this remains a speculative premise requiring validation. Further studies are also needed to clarify the underlying mechanisms of this combination and to identify predictive biomarkers for patient selection.

31 Dec 2026·INTERNATIONAL JOURNAL OF HYPERTHERMIA

Focused ultrasound ablation surgery combined with immune checkpoint inhibition in driver-gene wild-type NSCLC with liver metastasis: a feasibility study

Article

Author: Wang, Ting ; Chen, Jinyun ; Ouyang, Bing ; Chen, Li ; Chen, Wenzhi

BACKGROUND:

This single-arm, open-label clinical trial aimed to evaluate the preliminary safety, efficacy and feasibility of focused ultrasound ablation surgery (FUAS) sequential with immune checkpoint inhibitors (ICIs) in patients with driver-gene wild-type non-small cell lung cancer (NSCLC) and liver metastases.

MATERIALS AND METHODS:

Ten eligible patients received two cycles of FUAS sequential with ICIs. The ICIs used include Camrelizumab (7/10), Pembrolizumab (3/10) and Serplulimab used for immune rechallenge (1/10). Follow-up was conducted every 6 weeks ± 3 days, including imaging and hematological assessments. Treatment-related adverse events (AEs) were documented anytime.

RESULTS:

All participants demonstrated stable tolerability and safety in this trial. Immediate post-FUAS ablation rates ranged from 73% to 80%. The median follow-up time is 84 days (IQR, 42-127 days). From baseline to week 18, continuous shrinkage of both hepatic metastatic and target lesions was observed. The DCR of the tumor has reached 80% since the 2nd follow-up (12 weeks), and it remains at 50% until the 4th follow-up (24 weeks).

CONCLUSION:

FUAS sequential with ICIs suggests preliminary safety, activity and feasibility in treating driver-gene wild-type NSCLC patients with liver metastases, further validation is needed.

31 Dec 2026·Human Vaccines & Immunotherapeutics

Mapping research trends in esophageal cancer immunotherapy: A decade of thematic evolution and emerging priorities

Review

Author: Zang, Qiwei ; Jia, Huijun ; Wei, Hongyu ; Gong, Yifan ; Zhao, Chengguang

Immunotherapy has become a pivotal therapy for various cancers, including esophageal cancer, showing promising potential in improving survival rates and enabling personalized care. However, significant challenges occur in identifying predictive biomarkers, refining combination therapies, and managing immunotherapy-related adverse effects. This bibliometric study analyzed publications related to the use of immunotherapy in esophageal cancer management over a 10-y period (January 1, 2015, to October 14, 2024), retrieved from the Web of Science Core Collection. Keyword co-occurrence and co-citation analyses were performed to identify key contributors, central themes, and influential publications. A total of 545 publications on esophageal cancer immunotherapy were included in the analysis. A sharp increase in publication volume was observed beginning in 2019, with a peak between 2021 and 2023. China emerged as the leading contributor, accounting for 67.7% of the total output, while Zhengzhou University produced the highest number of publications among all institutions. Prominent individual contributors included Ken Kato and Shen Lin. Research hotspots centered on PD-1/PD-L1 inhibitors, combination therapies, and tumor microenvironment modulation. Notably, a clear temporal evolution in research focus was observed, with early studies emphasizing specific immune checkpoint targets and agents (e.g., PD-1, Pembrolizumab, and CTLA-4), followed by a shift toward mechanistic investigations involving the tumor microenvironment, treatment resistance, and prognosis. This study provides a comprehensive view of immunotherapy in the management of esophageal cancer, offering direction for future research and valuable insights for clinical innovation.

6,831

News (Medical) associated with Pembrolizumab

18 Jun 2026

·www.biospace.com

Minutes of the TME Pharma Annual General Meeting

Minutes of the TME Pharma Annual General Meeting Berlin, Germany, June 17, 2026, 6:30 p.m. CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for brain cancer and eye diseases, today announced that all resolutions were adopted at the meeting held on June 15. The Annual General Meeting of TME Pharma shareholders was held on Monday, June 15, 2026, chaired by Mr. Diede van den Ouden. Four shareholders were present, had granted proxies, or voted by mail. Together, they represented 6.87% of the shares and voting rights. The Annual General Meeting unanimously adopted all resolutions submitted by the Board of Directors. The voting results are available on the TME Pharma website. For more information, please contact: About TME Pharma TME Pharma is a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases. The Company’s lead compounds have been designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. Here is some additional background on the company’s assets that they are seeking to outlicense: NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer), which is being studied (GLORIA Phase 1/2 clinical trial) in newly-diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. The US FDA and the German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma, and TME Pharma was awarded Fast Track Designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma in Europe. NOX-E36 (emapticap pegol, L-RNA aptamer inhibiting CCL2 and related chemokines), which is being evaluated in ophthalmic diseases with a high need for well-tolerated therapies with anti-fibrotic effect. The Company is currently seeking opportunities to secure the financial resources to unlock the value of NOX-A12 and NOX-E36. These steps include: Raising funds from alternative sources Pursuing stable, cash-generating business opportunities to achieve positive operational cash flow for the Company Leveraging tax loss carry forwards Further information can be found at: . About the GLORIA Study The GLORIA (NCT04121455) study, currently on hold, is TME Pharma’s dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 in the expansion arm in which NOX-A12 is combined with radiotherapy and bevacizumab. About the OPTIMUS Study OPTIMUS (NCT04901741) is TME Pharma’s planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients. Disclaimer Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward-looking statements.” Forward-looking statements are based on TME Pharma’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and TME Pharma’s ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and TME Pharma undertakes no duty to update such information except as required under applicable law. Attachment ENG_Minutes of the TME Pharma Annual General Meeting

Orphan DrugPhase 2Fast Track

17 Jun 2026

·www.prnewswire.com

Nectin Therapeutics Reports Encouraging Phase 1 Results for NTX1088 in Combination with Keytruda® (pembrolizumab) at ASCO 2026

First-in-class anti-CD155 antibody demonstrated favorable safety profile and preliminary anti-tumor activity across multiple difficult-to-treat cancer types JERUSALEM, June 17, 2026 /PRNewswire/ -- Nectin Therapeutics, a clinical-stage oncology company developing first-in-class immuno-oncology and antibody-drug conjugate (ADC) therapies, today announced the presentation of Phase 1a/1b clinical data of NTX1088 in combination with pembrolizumab (Keytruda®), Merck's (known as MSD outside of the U.S. and Canada) anti-PD1 therapy, during an oral presentation at the 2026 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The data highlighted NTX1088, a first-in-class monoclonal antibody targeting the poliovirus receptor (PVR; CD155), a key regulator of the DNAM1 axis and an important driver of tumor-mediated immune suppression. The results were presented from the ongoing Phase 1a/1b, open-label, multicenter, dose-escalation and expansion study, NTX-1088-01 (KEYNOTE E92, NCT05378425), evaluating NTX1088 as both a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. A total of 91 patients were treated in the study., and NTX1088 was well tolerated, with no dose-limiting toxicities observed. Based on pharmacokinetics and target occupancy, a dose of 1,750 mg was selected as the recommended dose for expansion. Preliminary efficacy analysis focused on patients receiving active dose levels of NTX1088 (1200 and 1750 mg) in combination with pembrolizumab (200 mg). Among 41 evaluable patients, confirmed partial responses (PRs) were observed across multiple tumor types, including gastric, bladder, non-small cell lung cancer, squamous cell carcinoma of the head and neck, and melanoma. The study population represented a particularly challenging treatment setting, with a median of four prior lines of therapy and high rates of prior immune checkpoint inhibitors (CPIs) exposure. Additional patients achieved stable disease, and most responding patients were ongoing at data cutoff with a maximum treatment duration of 24 months. "These Phase 1 results indicate that NTX1088 in combination with pembrolizumab was well tolerated and demonstrated encouraging preliminary anti-tumor activity in a difficult-to-treat, CPI-pretreated population," said Sarina A. Piha-Paul, M.D., lead Principal Investigator of the NTX-1088-01 study at The University of Texas MD Anderson Cancer Center. "Based on these findings, further clinical evaluation in Phase 2 studies, including in less heavily pretreated and biomarker-enriched cohorts, is warranted." About Nectin Therapeutics, LTD. Nectin Therapeutics is a clinical stage biotechnology company devoted to transforming the lives of cancer patients by leveraging unique insights into Nectin pathways to develop the next generation of immune oncology (IO) therapies and antibody drug conjugates (ADCs). The company's differentiated therapies have the potential to set new standards for efficacy and patient response rates across various difficult-to-treat cancers. Nectin's technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies and antibody drug conjugates (ADCs). It has a world-class scientific and management team with deep experience in oncology drug development and successful track records in building biotechnology companies and developing innovative therapies. Nectin Therapeutics is a venture-backed, privately held company, funded by aMoon Fund, Peregrine Ventures, IBF, Integra Holdings, the Myeloma Investment Fund (MIF), GIBF and the Cancer Focus Fund. This study is supported by the European Innovation Council (EIC) KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, N.J., USA. Nectin Contact: Keren Paz, PhD Chief Development Officer [email protected] +1 201 218 1774 SOURCE Nectin Therapeutics, LTD. 21% more press release views with Request a Demo

Clinical ResultASCOPhase 1ImmunotherapyADC

16 Jun 2026

·firstwordpharma.com

FDA clears Merck & Co.'s Welireg, Keytruda combo in adjuvant kidney cancer

The FDA has approved a combination of Merck & Co.'s Keytruda (pembrolizumab) with the company's HIF-2α inhibitor Welireg (belzutifan) as an adjuvant treatment for adults with clear cell renal cell carcinoma (ccRCC) at risk of recurrence after surgery. The approval also applied to Keytruda's subcutaneous formulation, Keytruda Qlex (pembrolizumab/berahyaluronidase alfa-pmph). The decision, which follows a priority review, is based on the Phase III LITESPARK-022 trial, which enrolled 1841 patients with prior nephrectomy who were at intermediate-high or high risk of recurrence, or who had resected metastases with no evidence of disease. Patients were randomised to receive Welireg plus Keytruda as adjuvant therapy or Keytruda plus placebo. At a prespecified interim analysis, Welireg plus Keytruda was associated with a 28% benefit on the primary endpoint of disease-free survival (DFS), defined as time to recurrence, metastasis or death, with 186 events and 246 events in the Welireg and comparator arms, respectively. Median DFS wasn't reached in either arm, while overall survival (OS) data weren't mature at the interim analysis. Welireg already has a kidney cancer indication, having been approved in late 2023 for advanced RCC patients previously treated with PD-1/L1 and VEGF-targeted therapies (see – KOL Views Q&A: Welireg's safety will aid Merck & Co.'s upstream ambitions in RCC). Meanwhile, Friday's approval gives Keytruda it's fourth kidney cancer indication following two in the first-line advanced setting with Pfizer's Inlyta (axitinib) or Eisai's Lenvima (lenvatinib), and another in the post-nephrectomy setting based on results from the KEYNOTE-564 trial, where it showed a significant 38% improvement in OS in patients with high-risk disease. However, several experts interviewed by FirstWord for a Therapy Trends report last year indicated they planned to stick with Bristol Myers Squibb's Opdivo (nivolumab) for immuno-oncology combinations in RCC given the uncertainty around treatment sequencing (see – Spotlight On: Opdivo combos hold firm in RCC, despite growing pressure from Keytruda). The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultDrug ApprovalPriority ReviewImmunotherapy

100 Deals associated with Pembrolizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10574	Pembrolizumab	L01XC18	DB09037

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Platinum-Resistant Primary Peritoneal Carcinoma	European Union	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Primary Peritoneal Carcinoma	Iceland	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Primary Peritoneal Carcinoma	Liechtenstein	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Primary Peritoneal Carcinoma	Norway	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	European Union	Merck & Co., Inc.	02 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	Iceland	Merck & Co., Inc.	02 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	Liechtenstein	Merck & Co., Inc.	02 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	Norway	Merck & Co., Inc.	02 Apr 2026
Mismatch repair-deficient Colonic Cancer	United States	Merck Sharp & Dohme Corp.	10 Feb 2026
Mismatch repair-deficient Colonic Cancer	United States	Merck Sharp & Dohme LLC	10 Feb 2026
Neoplasms	United States	Merck Sharp & Dohme Corp.	10 Feb 2026
Neoplasms	United States	Merck Sharp & Dohme LLC	10 Feb 2026
Ovarian Cancer	United States	Merck Sharp & Dohme Corp.	10 Feb 2026
Ovarian Cancer	United States	Merck Sharp & Dohme LLC	10 Feb 2026
Muscle Invasive Bladder Carcinoma	United States	Merck Sharp & Dohme Corp.	21 Nov 2025
Muscle Invasive Bladder Carcinoma	United States	Merck Sharp & Dohme LLC	21 Nov 2025
Locally Advanced Head and Neck Squamous Cell Carcinoma	European Union	Merck Sharp & Dohme BV	30 Oct 2025
Locally Advanced Head and Neck Squamous Cell Carcinoma	Iceland	Merck Sharp & Dohme BV	30 Oct 2025
Locally Advanced Head and Neck Squamous Cell Carcinoma	Liechtenstein	Merck Sharp & Dohme BV	30 Oct 2025
Locally Advanced Head and Neck Squamous Cell Carcinoma	Norway	Merck Sharp & Dohme BV	30 Oct 2025

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent Platinum-Resistant Ovarian Carcinoma	NDA/BLA	United States	Merck & Co., Inc.	20 Oct 2025
Small intestine carcinoma	NDA/BLA	European Union	Merck Sharp & Dohme Corp.	25 Mar 2022
Non-small cell lung cancer stage I	Phase 3	United States	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Australia	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Canada	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Taiwan Province	Merck Sharp & Dohme LLC	04 May 2026
MSS/pMMR/MSI-L Endometrial Carcinoma	Phase 3	China	MSD R&D (China) Co. Ltd.	31 Aug 2025
Platinum-Resistant Ovarian Carcinoma	Phase 3	United States	Mural Oncology, Inc.	10 Jan 2022
Platinum-Resistant Ovarian Carcinoma	Phase 3	Australia	Mural Oncology, Inc.	10 Jan 2022
Platinum-Resistant Ovarian Carcinoma	Phase 3	Austria	Mural Oncology, Inc.	10 Jan 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02617849 (Pubmed \| Oncoimmunology)	Phase 2	Melanoma	30	Pembrolizumab and Carboplatin/ Paclitaxel	dxdbanmomy(xyudwketjm) = suocajzcor kjkteppvgu (xlifodaorv ) View more	Negative	31 Dec 2026
NCT03213041 (CTgov)	Phase 2	Breast cancer recurrent \| Triple Negative Breast Cancer \| Metastatic breast cancer ... View more	12	Laboratory Biomarker Analysis+Carboplatin+Pembrolizumab	crzufewqtr(xdkehavwgh) = mlyesjvejv rfzlvyfcyd (twaomatfhn, xexllatfyg - ljedbzwjhn) View more	-	17 Jun 2026
NCT03657641 (CTgov)	Phase 1/2	Metastatic Colorectal Carcinoma	73	regorafenib+Pembrolizumab (Phase I, Dose Level 1)	uuigxdlinm = yvujmarkyp jcsnwmygdv (trvyysenhy, dglnbwkhqc - gyjlryxnnf) View more	-	16 Jun 2026
				regorafenib+Pembrolizumab (Phase I, Dose Level 2)	uuigxdlinm = vcnnagmzsv jcsnwmygdv (trvyysenhy, riallffkde - einhdaique) View more
NCT04632459 (CTgov)	Phase 2	Metastatic gastric adenocarcinoma \| Metastatic Gastric Carcinoma	26	pembrolizumab+ramucirumab	ucbyxmxjhp = zwmieyshsk thwqfikaxg (wbqxibgfkp, lpxpeaqmop - dcstfodrgf) View more	-	05 Jun 2026
NCT04895735 (MC200708, CTgov)	Phase 2	Salivary gland cancer recurrent \| Metastatic salivary gland cancer \| Adenoid Cystic Carcinoma	45	pembrolizumab+pemetrexed disodium (Cohort A (Adenoid Cystic Carcinoma))	glvhezcrha = iokpjihjuc xwglmoukmn (vylsbztbro, dekqgwrwvn - yhmbvtsnyq) View more	-	04 Jun 2026
				pembrolizumab+pemetrexed disodium (Cohort A1 (ACC Patients Enrolled Starting With MCCC Amendment 3))	glvhezcrha = nwflsvcdbq xwglmoukmn (vylsbztbro, hytzorrdap - lyoxbvcxfc)
NCT04955743 (CTgov)	Phase 2	Renal Cell Carcinoma \| Metastatic melanoma \| Brain metastases	18	Pembrolizumab+Lenvatinib (Cohort 1: Melanoma)	nqdifracyz = biwrwlydol dzjakxfbdu (wdbtdjgaqp, iauhdaqhcz - glblvthnud) View more	-	04 Jun 2026
				Pembrolizumab+Lenvatinib (Cohort 2: Renal Cell Carcinoma)	nqdifracyz = gkcomjpevi dzjakxfbdu (wdbtdjgaqp, yetvojeued - ebdlghondi) View more
PLANeT (ASCO2026)	Phase 2	Triple Negative Breast Cancer Neoadjuvant	157	pembrolizumab + chemotherapy	eunwphbvfc(eahcldyfke) = rbomrhzdui oovrkysbep (jsrxleaamd ) View more	Positive	29 May 2026
				chemotherapy alone	eunwphbvfc(eahcldyfke) = efzpfmppzy oovrkysbep (jsrxleaamd ) View more
ASCO2026	Not Applicable	Locally Advanced Rectal Carcinoma Neoadjuvant PD-L1	24	modified FOLFOX6 plus pembrolizumab	xjdybgwien(pasxfkvhln) = Grade 1-2 toxicities included fatigue (42%), nausea (29%), and transaminitis (17%); Grade 3 events were limited to neutropenia (8%) and immune-mediated thyroiditis (4%). No Grade 4-5 toxicities occurred. xqvoubpoxk (ebsymeyrsd )	Positive	29 May 2026
NCT06736379 (ASCO2026)	Phase 1	Head and Neck Neoplasms Neoadjuvant	36	VLPONC-01	pxeeumrgcf(vfnrmsluif) = tdwpnjalbp wxfakrlyun (zyjapqcxie )	Positive	29 May 2026
				VLPONC-01 + Pembrolizumab	sothwhuzfh(obnzsbulgj) = wzvxeebgmj fqbjkzzscx (dskxzuwuzl ) View more
NCT05558982 (EXPEL PANC, ASCO2026)	Phase 2	Advanced Pancreatic Ductal Adenocarcinoma Second line MSI-H \| MSS	21	BXCL701 0.2 mg PO BID (days 1-7) → 0.3 mg BID (days 8-14+) + BXCL701 0.2 mg PO BID (days 1-7) → 0.3 mg BID (days 8-14	adiemfdfoo(rxbhbasntf) = bbfqtdcjvz yqjcxnkemj (fyknxossuv ) View more	Negative	29 May 2026

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Pembrolizumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation